clinical-trials
11 stories tagged "clinical-trials"
The Evolutionary Fix for Drug Resistance Works Best on a Tumor Too Small to Find
City St George's mathematicians say hitting a tumor at its weakest moment can drive it extinct. Their own model clears 95 percent only below 7 million cells, far smaller than any tumor a scan can find.
Infectious DiseaseDavid Ho's Lab Built an Antibody to Neutralize Nearly Every Strain of HIV. Its First Test in People With the Virus Held for Two Weeks.
Fifty-four volunteers, nine with HIV, and just three with virus still in their blood. The engineered antibody drove their viral load down as much as ninetyfold, then lost the ground within a week as it drained away.
InvestigationsNEJM Retracted the Study That Approved Amgen's Vasculitis Drug. It Had Never Done That in 200 Years.
The FDA says the drug's superiority result came from re-scoring nine patients after the trial was unblinded. It is still on U.S. shelves while Amgen fights the withdrawal.
CancerNo Gene Editing, No Catheter Into the Skull: A Pediatric Brain-Cancer T-Cell Trial Reported One Complete Response in 33 Young Patients
Children with diffuse pontine glioma rarely live past a year. A first-in-human trial infused 33 young patients with pediatric brain tumors, including DIPG, with T cells trained on three tumor proteins, no genetic engineering, and reported one complete response and three survivors still alive years l
CancerTwenty Years of Nothing on Brain Cancer, and the Best New Lead Is a Vitamin Nobody Can Patent
A University of Calgary trial added high-dose niacin to standard glioblastoma treatment and reported 82% of 24 patients progression-free at six months. The design is single-arm and early, but the molecule is a cheap, unpatentable vitamin.
InvestigationsThe Knee Procedure That Barely Beats a Convincing Fake
A university press release pitches a minimally invasive knee procedure as a way to delay joint replacement, but the only sham-controlled trials show the fake version works nearly as well.
CancerIvermectin and Cancer: The Review the Horse-Paste Crowd Wasn't Supposed to Get
A 2025 systematic review finds coherent anticancer biology in ivermectin across ten tumor types. The human evidence to match it does not exist. The question of why is what the punchline was designed to bury.
Infectious DiseaseThe cheaper staph antibiotic just won the biggest trial ever run
The largest randomized trial ever run for staph bloodstream infection finds the cheap generic antibiotic cefazolin works as well as the older standard, with less kidney damage and no pharma money behind the answer.
Infectious DiseaseThe AI Vaccine That 'Passed' Its First Trial Three Years Ago
Cambridge finished the Phase 1 trial in 2023. The press tour arrived in 2026. The paper, when you read it, said the immunogenicity was modest.
CancerALTAIR Missed Its Primary Endpoint. The Press Tour Found Something Else.
A phase 3 trial testing chemotherapy in ctDNA-positive colorectal cancer patients missed its primary endpoint at p=0.107, and a post-hoc reanalysis is doing the public-facing work.
CancerPancreatic cancer's undruggable wall just cracked. The follow-up is 8.5 months and the money was already placed.
Revolution Medicines' daraxonrasib nearly doubled median overall survival versus chemotherapy in previously treated metastatic pancreatic cancer at ASCO 2026, with 8.5 months of follow-up and a two-billion-dollar Royalty Pharma deal already riding on what comes next.